drug development

Aayam is a therapeutics company focused on delivering affordable and accessible therapeutics to patients. It uses a unique drug development technology platform called LADR 4 and aims to create a global collaborative network for drug discovery and development.

drug discovery

AB Science is a pharmaceutical company based in Paris, France, that develops two main compounds: masitinib, a highly selective tyrosine kinase inhibitor, and AB8939. The company also offers a veterinary medicine, Masivet®. It publishes clinical pipeline information, scientific publications, and regulated financial information.

clinical research

Acesis BioMed is a Colorado (USA) and London (UK) based biomedical company operating through Acesis Holdings Corporation and its subsidiaries Acesis Biomed US, Inc. and Acesis Biomed Ltd. It develops a platform of oral drug candidates for metabolic and endocrine disorders, initially focusing on male hypogonadism (low T) and related co-morbidities. Its proprietary first-in-class T peptide modulator is designed as a non-steroid alternative to Testosterone Replacement Therapy.

multigram-scale drug productionpeptide drug designpreclinical researchR&D via academic centers and CROs

Actinogen Medical Ltd (ACN 086 778 476) is an ASX-listed (code ACW) clinical-stage company developing Xanamem® (emestedastat), an oral therapeutic that controls levels of the stress hormone cortisol in the brain by inhibiting the 11β-HSD1 enzyme. It is developing Xanamem for Alzheimer's disease, Major Depressive Disorder, and other neurological conditions, and has conducted multiple clinical trials including a Phase 2b/3 Alzheimer's disease trial.

clinical developmentclinical trials

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator), is under evaluation for brain injury recovery including post-stroke and traumatic brain injury. It also advances GABAB PAM programs for substance use disorders and chronic cough, and holds a 20% equity interest in Neurosterix LLC.

allosteric modulator developmentclinical-stage pharmaceutical research

Adiposs is a biotech start-up and spin-off from the University of Geneva, incorporated in the Canton of Geneva, Switzerland. It is developing ImageBAT®, a first-in-class contrast agent for brown fat and the first diagnostic imaging product to identify patients with increased risks of cancer progression, higher risk of treatment failure and shorter survival. Its core team consists of four biotech entrepreneurs with over 80 years of combined drug development experience.

contrast agent developmentmedical imaging

Adiso Therapeutics creates medicines to treat inflammatory diseases, aiming to improve the lives of patients and their families. The company is advancing a pipeline of multi-modal agents with novel mechanisms of action and a precision therapeutic approach, including ADS032, a first-in-class dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for respiratory and dermal inflammation, and ADS024, an orally dosed single-strain live biotherapeutic product.

pre-clinical development

Advertent Biotherapeutics, Inc. is a privately held biotechnology company advancing new therapies to help people maintain strength and mobility when muscle is damaged by genetic diseases, injury, or aging. Founded in 2019 as a spin-out from Michigan State University, it combines expertise in growth factor biology, muscle pathology, and drug development to build first-in-class biologics that protect muscle quality over the long term.

biologics discoveryIND-enabling studiespreclinical developmentstructure-guided protein engineering

AgeneBio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapeutics for patients at risk for neurological and psychiatric conditions, with the goal of preserving and restoring brain function. Its lead late-stage clinical program, AGB101, is being evaluated for amnestic mild cognitive impairment due to Alzheimer's disease (MCI due to AD) in the HOPE4MCI Phase 2b trial. It also has a discovery program developing GABA(A) α5 positive allosteric modulators.

Chemistry Manufacturing & Controls (CM&C) developmentclinical developmentdrug discovery

Aisa Pharma is a privately held, clinical-stage biopharmaceutical development company dedicated to bringing new disease-modifying treatments to patients with rare serious diseases. It focuses on repurposing and optimizing select calcium channel blockers, and its lead program is developing AISA-021, an oral therapy targeting N-type calcium channels for Raynaud's phenomenon associated with systemic sclerosis (scleroderma). The company is headquartered in Boston, Massachusetts, with additional presence in Sydney, Australia.

clinical developmentclinical operationsCMCRegulatory Affairsrepurposing and optimizing calcium channel blockers

Akanocure is a drug development company with a focus on orphan and unmet needs in oncology. Applying expertise throughout the drug discovery and development process, it creates novel small molecules intended to positively impact the lives of cancer patients. Its mission is to find therapeutic approaches that block metastatic processes, and it integrates chemical methodology development with classic drug discovery expertise through collaboration with industry leaders, academia, and government.

chemical methodology developmentchemistry platformdrug discoverysmall molecule development

AKAVA Therapeutics is a biotechnology company developing first-in-class small molecule inhibition therapeutics for neurodegenerative diseases and cancers. Its lead compound AKV9 targets protein aggregation and has been investigated in ALS, hereditary spastic paraplegia, frontotemporal dementia, and Alzheimer's disease. The company was established in 2019 as a commercialization arm for compounds from the Silverman Laboratory at Northwestern University.

drug discoverysmall-molecule therapeutics

ALIGOS Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH). The company targets liver and viral diseases with best-in-class therapies, leveraging medicinal chemistry and biology teams to build a differentiated pipeline.

biology researchdrug discoverymedicinal chemistry

AliquantumRx is a near-clinical infectious-disease company focused on eliminating liver-stage malaria relapse. It is developing Cethromycin HCl through its CALM (Cethromycin Against Liver-Stage Malaria) program, a short-course, G6PD testing-independent oral therapy designed to eliminate dormant liver-stage malaria and prevent relapse. The company is supported by over $6M in non-dilutive funding for IND-enabling studies and early clinical development and is pursuing human proof-of-concept and potential Priority Review Voucher eligibility.

clinical developmentIND-enabling studies

Allterum Therapeutics is an early-stage biotechnology company developing precision oncology and inflammation therapeutics. Its lead program, 4A10, is an anti-CD127 monoclonal antibody targeting the CD127 pathway (IL-7 receptor complex) for relapsed leukemia, acute lymphoblastic leukemia, B-cell malignancies, lymphomas, and CD127-expressing solid tumors. The 4A10 antibody was developed at the National Cancer Institute and licensed exclusively to Fannin; Allterum is a Fannin portfolio company.

clinical developmentmonoclonal antibody developmentpreclinical studiestranslational science

Allysta Pharmaceuticals is a private venture-backed clinical stage biopharmaceutical focused on rare diseases with high unmet needs. It develops first-in-class therapeutic peptides with anti-fibrotic, anti-inflammatory, cell regenerative, and metabolic effects. Its lead drug ALY688ER is an extended release formulation and potent activator of adiponectin signaling pathways; ALY688 is described as the first adiponectin receptor agonist to enter human testing. Lead indication is Duchenne muscular dystrophy.

clinical-stage biopharmaceutical researchtherapeutic peptide development

Alphyn Biologics is a clinical-stage dermatology life science company developing first-in-class Multi-Target Therapeutics (MTT) for severe and prevalent skin diseases based on its Zabalafin Platform (AB-101 Platform). Its lead product candidate, zabalafin hydrogel (AB-101a), is in development for mild-to-moderate atopic dermatitis and has completed a Phase 2a clinical trial. The company became operational in March 2020 and is based in Annapolis, Maryland and Cincinnati, Ohio, with an Australian subsidiary and a European presence in Vienna, Austria.

clinical trialsQuality Systems ManagementRegulatory Affairs

Alteron Therapeutics develops first-in-class TDP-43 inhibitors, the ALTA drug series, to find cures for neurodegeneration and cystic fibrosis. The company targets TDP-43 toxicity, which contributes to ALS, Alzheimer's disease, and frontotemporal lobar degeneration. Its leading drug candidate is orally bioavailable, crosses the blood-brain barrier, and shows potential to reverse ALS symptoms.

molecular dockingNMR structuresTDP-43 inhibition

Anebulo Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for cannabis-induced toxicity, including acute cannabis-induced CNS depression in children and acute cannabinoid intoxication (ACI) in adults. Its lead development candidate is selonabant, a reversal agent for cannabis-induced toxicities.

clinical trials

Anivive Lifesciences, Inc. is a next generation animal health company that combines artificial intelligence software, biotech, and veterinary medicine to serve the unmet medical needs of pets. It develops a pipeline of products to treat cancers, infectious diseases, and endocrine conditions, and is pursuing a canine Valley Fever vaccine and an FIP therapeutic. Incorporated September 25, 2015, headquartered in Long Beach, CA.

artificial intelligence drug discoverypredictive analyticsspecialty pathology servicestumor genotypingveterinary oncology

Annagen BioTech LLC is a group of scientists investigating the mechanism of aging and translating scientific data into products. They developed a facial cream with a patent-pending formula under the trade name The American Mollusk Beauty, and are close to launching it for commercial distribution. They also conduct R&D on a non-PCR based in vitro diagnostic system (NIDS) for mRNA detection and on small molecules for wound healing.

aging researchdiagnostic assay developmentmolecular biologyR&Dtissue culture

Antidote Therapeutics is a science-driven biopharmaceutical company developing first-in-class nicotine-blocking therapies to treat diseases caused or worsened by nicotine. Its proprietary treatments target rare vascular diseases and addiction, including a fully human anti-nicotine monoclonal antibody. Initial indications include orphan vascular diseases in smokers such as Buerger's Disease and Critical Limb Ischemia.

clinical research collaborationdrug discoveryimmunotherapeutic approachesmonoclonal antibody development

AntiRadical Therapeutics LLC is a company focused on anti-aging therapeutics addressing unmet medical needs for the aging demographic. It develops DETOPS, a drug based on stable nitroxide free radicals with antioxidant properties that mimic endogenous superoxide dismutase and may affect nitric oxide pathways, cellular signalling and vascular dynamics. DETOPS has undergone extensive preclinical testing and can be administered orally, dermally (topical), or by intramuscular injection.

anti-aging researchpreclinical testing

Argenica Therapeutics Limited (ASX:AGN) is a clinical stage drug development company developing novel neuroprotective therapeutics to reduce brain damage after stroke and other acute brain injuries. Its lead candidate ARG-007, a cationic arginine-rich peptide, is based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science. ARG-007 has completed a Phase 1 clinical trial and is being tested in a Phase 2 clinical trial in acute ischaemic stroke patients in Australia.

clinical trialscommercialisation of therapeuticspre-clinical research